Comparison of the effect of pegfilgrastim with filgrastim on the neutrophil count of cancer patients under chemotherapy.

Comparison of the effect of pegfilgrastim with filgrastim on the neutrophil count of cancer patients under chemotherapy, a randomization clinical trial.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180119038433N3

Enrollment

Registered

2020-09-26

Start date

2020-10-22

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy. Encounter for antineoplastic chemotherapy and immunotherapy

Interventions

Intervention 1: Intervention group: Patients are in this group for a period of chemotherapy. For patients 24 hours after chemotherapy, 5 ug/kg of filgrastim (brand name: Tinagrast, a product of Arya

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Having satisfaction Age over 18 years Chemotherapy in Omid ward of Kowsar hospital History of at least 1 course of chemotherapy Use myelosuppression chemotherapy drugs Lack of allergy to pegfilrastim and filgrastim Absence of underlying diseases

Exclusion criteria

Exclusion criteria: Patients with underlying disease Allergy to pegfilgrastim or filgrastim Severe fever and neutropenia in previous courses of chemotherapy Patients with advanced cancer Not consent to participate in the study

Design outcomes

Primary

Measure	Time frame
Neutrophil count. Timepoint: Before the intervention and before the next round of chemotherapy. Method of measurement: Complete Blood cell count and Diffrential count.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Amir Sarabi

Semnan University of Medical Sciences

drsam_amir@yahoo.com+98 23 3142 2001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026